Medications That Cannot Be Given Through a PEG Tube

No single list of banned medications applies to every PEG tube patient, but several categories of drugs should never be crushed and pushed through a feeding tube without careful evaluation. The most frequently problematic are controlled-release and enteric-coated formulations, where crushing destroys the mechanism that controls how and where the drug is absorbed. Beyond formulation issues, some medications interact with enteral feeding formulas, others physically clog the tube, and still others are absorbed into the tube material itself. The reality is messier than a simple “yes or no” list, and the gap between what clinicians need to know and what drug labels actually tell them is wider than you might expect.

Why Crushing the Wrong Pill Is Dangerous

The most common reason a medication cannot safely go through a PEG tube is that it was designed to release its active ingredient slowly or in a specific part of the gut. Controlled-release tablets (sometimes labeled as ER, XR, XL, SR, or CR) contain a drug matrix or coating that meters out the dose over hours. Crushing one of these tablets dumps the entire dose at once, which can cause a dangerous spike in blood levels followed by a period with no drug in the system at all. For some medications, that spike alone is enough to cause serious harm.

Enteric-coated formulations present a different problem. The coating is designed to survive stomach acid and dissolve only once the pill reaches the more alkaline environment of the small intestine. This protects either the stomach lining from an irritating drug or the drug itself from being destroyed by acid. Crushing removes that protection entirely. Proton pump inhibitors like pantoprazole are a classic example: crush the enteric-coated tablet and much of the active drug is degraded by stomach acid before it can do anything useful.

A cross-sectional study of geriatric patients receiving home tube feeding found that the single leading cause of medication errors was giving formulations unsuitable for enteral tubes, accounting for about a third of all errors detected. Controlled-release and enteric-coated drugs were the most common culprits, including medications like levetiracetam extended-release, pantoprazole, tamsulosin, and enteric-coated aspirin.¹ In many of these cases, a liquid or immediate-release alternative existed but had not been prescribed.

Drugs That Clash With Enteral Formulas

Even when a drug can physically pass through the tube, the enteral feeding formula running through the same tube can interfere with absorption so severely that the medication becomes essentially useless. This is not a minor inconvenience. For drugs with narrow therapeutic windows, the difference between adequate and inadequate absorption can mean the difference between seizure control and a breakthrough seizure, or between a treated infection and a resistant one.

Phenytoin is the textbook case. When phenytoin suspension is given through a feeding tube during continuous enteral nutrition, absorption drops dramatically. Standard doses of 300 to 500 mg per day can produce almost undetectable blood levels when co-administered with tube feeds.² The mechanism is not entirely settled, but the drug appears to bind to proteins in the formula and to the tubing itself, and when the tube tip sits in the duodenum rather than the stomach, the reduced time for dissolution makes things worse.³ The standard workaround is to pause feeds for one to two hours before and after giving phenytoin, but even then, levels need close monitoring.

Fluoroquinolone antibiotics like ciprofloxacin run into a similar problem. When ciprofloxacin was co-administered with an enteral formula in healthy volunteers, both the peak blood level and total absorption dropped significantly compared with administration with water alone.⁴ The likely culprit is the divalent cations (calcium, magnesium, iron) in the formula, which bind to the antibiotic and prevent it from being absorbed. This is the same reason you are told not to take ciprofloxacin with a glass of milk. In a tube-fed patient, though, the feeding schedule and the drug schedule overlap far more consistently than they would for someone eating meals, making the interaction harder to avoid.

Levothyroxine, the thyroid replacement hormone, presents yet another interaction pattern. In a study of patients receiving continuous enteral nutrition alongside levothyroxine through their tubes, more than half developed hypothyroidism within two to three weeks, some of it severe enough to produce overtly abnormal thyroid function.⁵ Levothyroxine is best absorbed on an empty stomach, and the continuous presence of formula in the stomach and small intestine undermines that absorption. Pausing feeds, ideally for at least an hour before and after the dose, is the usual recommendation, but in patients who depend on continuous nutrition this creates a genuine clinical dilemma.

How Tubes Get Clogged

Tube clogging is one of the most common practical problems in enteral medication delivery, and it tends to be underestimated until it happens. A clogged tube can mean a trip to the emergency department for replacement, especially for patients at home or in long-term care settings, adding cost and discomfort to an already burdensome situation.⁶

Clogging happens through several mechanisms. The simplest is physical: crushed tablets that are not fully dissolved, granules from capsule contents, or medications with a gummy or paste-like consistency can accumulate inside the narrow lumen of a feeding tube. Bulk-forming agents like psyllium are notorious for this. In one study of enterally fed patients receiving psyllium for diarrhea management, small-bore feeding tubes occluded at a rate that required tube replacement in roughly one in eight patients.⁷

A subtler clogging mechanism involves acid-formula interactions. Many liquid medications are acidic, and when an acidic solution meets an enteral formula that contains intact proteins (particularly casein), the proteins can coagulate into a gel-like mass. Research has shown that common enteral formulas begin clumping at a pH around 4.6, and at that pH or below, coagulation can happen within seconds.⁸ Acidic liquid medications pushed through the tube without adequate flushing between the drug and the formula are a frequent trigger for this kind of clog.⁹ The solution is straightforward but often skipped in practice: flush the tube with water before and after each medication, and never mix acidic liquids directly into the feeding formula.

Sucralfate deserves special mention. This stomach-coating drug forms a viscous paste by design, and when combined with antacids and tube feeds, it can contribute to bezoar formation. A case report described an esophageal bezoar in a ventilated patient receiving sucralfate, antacid, and tube feeding simultaneously through a nasogastric tube.¹⁰ Sucralfate is generally considered a poor candidate for feeding tube administration for exactly this reason.

When the Tube Itself Absorbs the Drug

A problem that gets far less attention than clogging or formula interactions is drug sorption, where the active medication is absorbed into the tube material rather than passing through to the patient. Feeding tubes are made from either silicone or polyurethane, and both materials can bind certain types of drugs.

Research using simulated infusion setups has demonstrated that silicone and polyurethane catheters can cause extremely high losses of diazepam and insulin due to sorption, while a control drug like paracetamol passed through without significant loss.¹¹ The clinical implication is straightforward: if a meaningful fraction of the dose is sticking to the inside of the tube, the patient is being under-dosed even though the full amount was pushed through. Lipophilic drugs (those that dissolve readily in fats rather than water) tend to be the worst offenders for sorption, because the polymer materials in tubing are more attractive to fat-soluble molecules.

This problem is difficult to detect at the bedside. Unlike a clogged tube, which announces itself immediately, sorption is invisible. The medication appears to have been delivered successfully, but the patient’s blood levels remain lower than expected. In a hospital, this might prompt dose escalation or a switch to intravenous delivery. At home, it might simply look like the medication is not working.

Sorbitol and Hidden Excipients

When a liquid formulation is chosen specifically because it seems like a safer option for tube delivery than a crushed tablet, the inactive ingredients in that liquid can introduce their own problems. Sorbitol, a sugar alcohol widely used as a sweetener and vehicle in liquid medications, is a common culprit. Many medicinal elixirs and liquid preparations contain enough sorbitol to cause osmotic diarrhea, especially in tube-fed patients who may already have sensitive gastrointestinal tracts.¹²

The challenge is that diarrhea in tube-fed patients is often blamed on the feeding formula itself, and the team may switch formulas, adjust the rate, or add anti-diarrheal medications when the actual cause is the sorbitol in one or more liquid drugs being given through the tube. When a tube-fed patient develops unexplained diarrhea, reviewing the sorbitol content of every liquid medication on their list is a worthwhile step before changing anything else. Some liquid formulations contain surprisingly large amounts per dose, and when multiple sorbitol-containing liquids are given throughout the day, the cumulative load can easily exceed the threshold that causes GI symptoms.

Where the Tube Ends Matters

Not all feeding tubes deliver medications to the same place. A standard PEG tube opens into the stomach, which is where orally swallowed medications would normally arrive. But some patients have jejunostomy tubes (PEJ or J-tubes), which bypass the stomach entirely and deliver contents directly into the small intestine. This distinction matters because many drugs are formulated with the assumption that they will encounter stomach acid, undergo initial dissolution in the stomach’s acidic environment, and then move into the intestine for absorption.

A systematic review of medication stability via enteral tubes highlighted that anatomical site of delivery can meaningfully change how much drug reaches the bloodstream. For example, trovafloxacin administered into the duodenum showed reduced systemic exposure compared with gastric administration, likely because of differences in pH, enzymatic activity, and the presence of efflux transporters in the small intestine.¹³ The finding reinforces a broader point: you cannot assume that a drug delivered past the stomach will behave the same as one delivered into it. For patients with jejunal tubes, the list of potentially problematic medications grows, and the need for pharmacist involvement in medication planning increases.

Acid-dependent drugs are a clear concern for jejunal delivery. Medications that require an acidic environment for dissolution or activation (including many antifungals like ketoconazole and itraconazole capsules) may not dissolve or absorb adequately when delivered past the stomach. On the other hand, enteric-coated drugs, which are designed to resist stomach acid and dissolve in the alkaline intestine, might seem like a good fit for jejunal tubes. But the coating still needs to dissolve properly, and the transit time through the jejunum may not allow for complete release.

Hazardous Drugs and Caregiver Safety

A separate but important category involves medications classified as hazardous, including many chemotherapy agents and certain hormonal therapies. Crushing these drugs to deliver them through a tube creates airborne particles and dust that pose a safety risk to whoever is doing the crushing. In a hospital pharmacy, this can be managed with specialized equipment and safety protocols. At home, a family caregiver crushing a hazardous tablet at the kitchen table with a pill crusher has essentially no protection.

This concern has driven development of closed-system devices designed specifically for crushing and dispersing hazardous tablets for enteral administration. These devices aim to contain the drug throughout the crushing and dissolution process, reducing exposure to caregivers and minimizing environmental contamination. For patients who require hazardous medications and have no alternative route, such devices offer a practical middle ground between refusing to give the drug and exposing caregivers to unnecessary risk.

The Scale of the Problem

Medication errors in tube-fed patients are not rare events. The geriatric home care study mentioned earlier found that nearly all patients (over 93%) had at least one medication error related to their tube feeding, and roughly half of all prescribed medications had some form of error associated with their enteral delivery.¹ The errors broke down into several categories: giving drugs unsuitable for the tube, prescribing solid forms when liquids were commercially available, improper preparation by caregivers at home, and drug-nutrient interactions that had not been addressed.

These numbers likely understate the true scope. At home, many errors go undetected unless they cause an obvious clinical problem like a clogged tube or a dramatic change in the patient’s condition. Subclinical under-dosing from sorption or formula interactions may never be identified as a medication delivery problem. The downstream costs are real: clogged tubes require replacement, under-dosed patients may need hospitalizations for complications of poorly controlled conditions, and adverse effects from dose-dumping of crushed extended-release drugs add to the clinical burden.⁶

Drug Labels Rarely Tell You What You Need

You might assume that drug manufacturers provide clear guidance on whether their product can be given through a feeding tube. They usually don’t. A landscape analysis of drug product labeling found only 71 unique drug products with any labeling information related to enteral tube administration. Among those that did include such information, the coverage was uneven: while most mentioned the type of feeding tube, fewer than half discussed tube size, only about one in seven addressed tubing material, and fewer than one in ten discussed the timing of feeds relative to dosing. Information about how tube delivery affects the drug’s absorption appeared in fewer than one in five labels.¹⁴

This means that for the vast majority of medications, the decision about whether and how to give a drug through a PEG tube is made by clinicians and pharmacists working from scattered evidence, institutional protocols, and experience rather than from manufacturer guidance. It is one of those areas of medicine where the evidence base has not caught up with the daily reality of patient care. Patients and caregivers should not hesitate to ask a pharmacist to review every medication on the list when tube feeding begins or when medications change. A pharmacist can identify drugs that need a formulation switch, flag timing issues with feeds, and flag potential clogging risks before they become an emergency.

Medications Often Flagged for PEG Tube Concerns

While no universal banned list exists, several categories and specific drugs come up repeatedly in clinical practice as problematic for enteral tube delivery:

Extended-release formulations: Nifedipine XL, verapamil SR, oxycodone ER, metoprolol succinate ER, levetiracetam XR, and similar products. Crushing eliminates the controlled-release mechanism. An immediate-release version or a different drug in the same class is usually available.
Enteric-coated tablets: Pantoprazole, enteric-coated aspirin, duloxetine (enteric-coated pellets inside a capsule), mycophenolate sodium. Crushing exposes the drug to acid degradation or exposes the stomach to an irritating drug.
Drugs with severe formula interactions: Phenytoin, ciprofloxacin, levothyroxine, and warfarin all have documented interactions with enteral formulas that reduce absorption. Feed-hold protocols or alternative routes are often needed.
Highly viscous or gel-forming drugs: Sucralfate, bulk-forming laxatives like psyllium, and cholestyramine powder can obstruct the tube.
Sublingual or buccal medications: Nitroglycerin sublingual tablets and fentanyl buccal tablets are designed for absorption through the oral mucosa. Putting them through a tube delivers them to the stomach, where absorption is different and often inadequate.
Hazardous drugs without a liquid form: Methotrexate tablets, certain hormonal agents, and other cytotoxic drugs pose a crushing safety risk and require specialized handling if no alternative route exists.

This list is not exhaustive, and new formulations are released regularly. The safest approach remains a medication-by-medication review with a pharmacist familiar with enteral drug delivery whenever a patient transitions to tube feeding or a new drug is added to their regimen.